John is an accomplished scientist and pharmaceutical executive with a passion for transforming innovative science into new medicines for patients in need.
John is the Global Head of Infectious Diseases at Roche Pharma Research and Early Development (pRED), based in Basel, Switzerland. He also plays key leadership roles in global pandemic preparedness, representing Roche on the Boards of the AMR Action Fund and the Intrepid Alliance, and on the Leadership Team of the FNIH/NIH-led ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines) public-private partnership. Prior to joining Roche in 2014, John was a Professor at the Salk Institute for Biological Studies in La Jolla, California. He has co-authored over 100 manuscripts. He is the recipient of the American Society for Microbiology's Eli Lilly and Company-ELANCO Research award, and is a co-recipient of the NIH office of the Director’s Award for his work on ACTIV. John is also a Fellow of the American Academy of Microbiology.